HHHG, you seem to be able to call a spade a spade and have been fairly accurate on your predictions lately and ability to buy, sell, and repeat for a small profit as we sadly watch the pps spiral down to almost nothing.
I'm an eternal optimist, not a pumper of this company, having been a shareholder long before the first introduction of Lipigesic M to the retail public. I will stick with this company to the bitter end if that is what it is going to be, as I feel there is tons of potential here. Any communications I've had with the company whether it be Russ, Patricia, or any other past company representatives, they have all given me reason to believe that they will not give up until they make this company a success.
I see the positives:
The company has an effective, natural, clinically proven migraine pain medication that has had retail exposure.
Russ Mitchell has been down this road before having brought other products to retailers, such as Coldeze
Puramed Bioscience has other Lipigesic products for other ailments such as tension headaches and sleeplessness.
The company is making investors aware that they intend to begin moving into the CBD product market
PMBS has a sublingual delivery method that is far superior to other methods.
We are lead to believe that the company plans a re-introduction of its original pain medication Lipigesic M, or same product under a new label, to the retail market in the near future.
Puramed works closely with US troops by providing Lipigesic M which could some day move the company closer to a government contract with this or many of the other products they have.
PMBS tends not to waste money on fluffy pr's likely many other penny stock companies do just to bolster their share price.
Low o/s shares in comparison to many other penny stocks.
Accumulation of the shares continues throughout the conversion phase, which indicates convertors are buying back many of their shares.
There are also the hurdles with PMBS when it comes to Lipigesic M being removed from store shelves, the outstanding shares increasing to where it is now, low pps due to note conversions, few corporate updates, struggle to raise capital (typical in penny stock land)
So with all of that on the table, I guess one just has to sit back and ask, with the price per share at $.0006 which is a comparison of $.055 when there was 13 million shares, and the company's share price topped out at an intraday high of $1.99 with just the mere introduction of one product to the retail market and no guaranteed revenue. What risk is here with investing long term now? I believe we can all do the math on that one, now factor in some revenue and new retailers, such as Walmart, additional products, government contract, etc., etc., etc.....
More positives;
No form t trades now for a few days
The dilutor (BMAK) on Friday's trading was on the bid and ask at $.0004 and $.0005 which should indicate the end of dilution/conversion/buy back.
A supportive accumulation pattern which leads investors to believe that the note convertors are buying back many of their shares as they see the potential in the company as well.
It appears the notes will be done this upcoming week.
What is your take on all of the above?
Sorry for the essay, rainy day, with nothing better to do then maybe play a few hands of cards and call a "spade a spade".
News 
Market Data 
Discover 
